ÅǸ޴º
Á¦¸ñ | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | µî·ÏÀÏ | 20150827 | ´Ù¿î·Îµå | |
---|---|---|---|---|---|
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
LANCET 384/9944 :665-73,2014 |
Copyright ¨Ï chamc, All rights reserved.